Autoimmunity BioSolutions is developing a personalized, genetically guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7R (sIL7R), a driver of poor therapeutic response in autoimmune disease. The therapy targets a genetically defined subpopulation marked by a highly prevalent SNP estimated in roughly 50% of the population that increases sIL7R expression. ABS is focused on indications including rheumatoid arthritis, lupus nephritis, and type 1 diabetes where elevated sIL7R has been associated with greater severity, progression, and reduced response to standard treatments. The company plans near-term work to complete animal model studies and patient bio-sample analyses in rheumatoid arthritis. ABS has raised $3.1 million in total seed capital following the $1M seed extension and is headquartered in Houston. The company positions its approach as differentiated from immunosuppressive standards of care and aims to enhance response in refractory patient populations with elevated sIL7R.

Total raised

$3M

Funding rounds

2

Latest round

Seed

Latest activity

May 2026